Use of estrogen antagonists and aromatase inhibitors in endometriosis

Current Opinion in Investigational Drugs

Volumn 4, Issue 10, 2003, Pages 1209-1212

  Viganò, Paola ^a   Mangioni, Silvia ^a   Odorizzi, Maria Paola ^a   Chiodini, Annalisa ^a   Rocca, Sabrina ^a   Chiodo, Ilda ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti estrogens; Aromatase inhibitors; Endometriosis; Estrogen antagonists; Letrozole; Raloxifene; SERM

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FORMESTANE; FULVESTRANT; GESTAGEN; GONADORELIN DERIVATIVE; LETROZOLE; MEGESTROL ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADD ON THERAPY; BREAST CANCER; CELL PROLIFERATION; CLINICAL TRIAL; CYST; DIARRHEA; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; ENDOMETRIOSIS; ENDOMETRIUM; ENZYME INHIBITION; ESTROGEN SYNTHESIS; HEADACHE; HOT FLUSH; HUMAN; IMPLANTATION; INFERTILITY; INHIBITION KINETICS; MONOTHERAPY; NAUSEA; NONHUMAN; OSTEOPOROSIS; OVARY; PATHOGENESIS; PREMENOPAUSE; REVIEW; SIDE EFFECT; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TREATMENT INDICATION; UTERUS MYOMA; UTERUS TUMOR; VAGINA BLEEDING; WEIGHT GAIN;

AROMATASE INHIBITORS; ENDOMETRIOSIS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS;

EID: 0242574375     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Mahutte NG, Arici A: Medical management of endometriosis-associated pain. Obstet Gynecol Clin North Am (2003) 30(1):133-150.
2. Missmer SA, Cramer DW: The epidemiology of endometriosis. Obstet Gynecol Clin North Am (2003) 30(1):1-19. A comprehensive review of the risk factors for endometriosis.
3. Vignali M, Infantino M, Matrone R, Chiodo I, Somigliana E, Busacca M, Viganò P: Endometriosis: Novel etiopathogenetic concepts and clinical perspectives. Fertil Steril (2002) 78(4):665-678.
4. Lake DE, Hudis C: Aromatase inhibitors in breast cancer: An update. Cancer Control (2002) 9(6):490-498.
5. Riggs BL, Hartmann LC: Selective estrogen-receptor modulators - Mechanisms of action and application to clinical practice. N Engl J Med (2003) 348(7):618-629. A detailed description of SERM structure and function.
6. Seli E, Berkkanoglu M, Arici A: Pathogenesis of endometriosis. Obstet Gynecol Clin North Am (2003) 30(1):41-61.
7. Bulun SE, Zeitoun KM, Takayama K, Noble L, Michael D, Simpson E, Johns A, Putnam M, Sasano H, Carr B: Aromatase expression in endometriosis: Biology and clinical perspectives. In: Understanding and Managing Endometriosis: Advances in Research and Practice. Lemay A, Maheux R (Eds), Parthenon Publishing, Quebec City, Quebec, Canada (1998):139-148.
8. Bulun SE, Zeitoun KM, Takayama K, Sasano H: Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update (2000) 6(5):413-418.
9. Miller WR, Anderson TJ, Dixon JM: Anti-tumor effects of letrozole. Cancer Invest (2002) 20(Suppl 2):15-21. An analysis of letrozole antitumor action and effects.
10. Fang Z, Yang S, Gurates B, Tamura M, Simpson E, Evans D, Bulun SE: Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue. J Clin Endocrinol Metab (2002) 87(7):3460-3466. A well conducted study performed in a murine model of endometriosis to demonstrate the importance of aromatase in the disease.
11. Zeitoun KM, Bulun SE: Aromatase: A key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril (1999) 72(6):961-969.
12. Scarpellini F, Sbracia M, Lecchini S, Frigo S, Scarpellini L: Aromatase inhibitors in the treatment of severe endometriosis. J Soc Gynecol Investig (2003) 10:223A.
13. Campos SM, Winer PE: Hormonal therapy in postmenopausal women with breast cancer. Oncology (2003) 64(4):289-299. A complete description of the categories of agents currently employed in the treatment of breast cancer in ER-positive women.
14. Miller CP: SERMs: Evolutionary chemistry, revolutional biology. Curr Pharm Des (2002) 8(23):2089-2111.
15. Meegan MJ, Lloyd DG: Advances in the science of estrogen receptor modulation. Curr Med Chem (2003) 10(3):181-210.
16. Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J, Jaffe RB: Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab (1998) 83(1):6-13. The only published study that has evaluated the effects of raloxifene in premenopausal women.
17. Swisher DK, Tague RM, Seyler DE: Effect of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats. Drug Dev Res (1995) 36:43-45.
18. Fanning P, Kuehl T, Lee R, Pearson S, Wincek T, Pliego J, Spiekerman A, Bryant HU, Rippy M: Video mapping to assess efficacy of an antiestrogen (raloxifene) on spontaneous endometriosis in the rhesus monkey, Macaca mulata. In: Bunkley Day Proceedings. Kuehl TJ (Ed), Texas A&M University Health Science Centre, Temple, TX, USA (1996) 6:51-61.
19. Johnston SR: Fulvestrant (AstraZeneca). Curr Opin Invest Drugs (2002) 3(2):305-312.